Live tape
Top 8, mentions 7d7,412NVDA1,293 mentions▲ +0.09GOOGL1,128 mentions▲ +0.04AVGO1,031 mentions▲ +0.05NKE1,013 mentions+0.02LULU956 mentions▲ +0.03TSLA894 mentions▲ +0.06META581 mentions▲ +0.05MSFT516 mentions▲ +0.06

Equity · Healthcare

RLAY

Relay Therapeutics, Inc. · NasdaqGM

$19 −0.03% 1D Finazon · prior-day close · Sep 4, 2026
Price · Chart
Our own end-of-day closes 61 sessions
$22.5 $12.5 10 Jun 4 Sep

The line runs $13.47 on 10 June through $19 on 4 September, on a scale from $12.5 to $22.5. Days the market did not trade hold the previous close, flat.

The chart above plots the price of RLAY over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 61 sessions over that window: $13.47 on 10 June 2026 through $19 on 4 September 2026.

Market cap $4.2B
52-week range $3.59 – $21
Avg volume 282.9K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 8, 2026

RLAY insider trades

SEC Form 4

RLAY has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 4 November 2025.

Date Insider Type Shares Value
03 Nov 2025 Patel Sanjiv President and CEO Sell 62,073 $435K
29 Oct 2025 Rahmer Peter See remarks Sell 21,394 $160K
28 Oct 2025 Bergstrom Donald A President, R&D Sell 30,897 $225K
28 Oct 2025 Catinazzo Thomas Chief Financial Officer Sell 21,664 $158K
28 Oct 2025 Rahmer Peter See remarks Sell 19,135 $139K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
04 Nov 2025 COATS LONNEL Award 207,931
04 Nov 2025 Dable Habib J Award 207,931

RLAY reported financials

SEC EDGAR XBRL

RLAY reported revenue of $15.4M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$276.5M.

Figure Reported Period
Revenue $15.4M 31 Dec 2025 fiscal year
Net income −$276.5M 31 Dec 2025 fiscal year
Diluted EPS −$1.61 31 Dec 2025 fiscal year
Total assets $967.5M 30 Jun 2026 at period end
Total equity $890.0M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

RLAY earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.41 $0M
31 Mar 2026 Q1 2026 $-0.41 $3M
31 Dec 2025 FY 2025 $-1.61 $15M
30 Sep 2025 Q3 2025 $-0.43
30 Jun 2025 Q2 2025 $-0.41 $1M
31 Mar 2025 Q1 2025 $-0.46 $8M
31 Dec 2024 FY 2024 $-2.36 $10M
30 Sep 2024 Q3 2024 $-0.63

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

RLAY institutional holders

SEC Form 13F

10 of the 45 institutional funds we track reported a RLAY position for the quarter ended 30 Jun 2026 — a combined $122.7M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Baker Bros. Advisors Added +143.7% shares 2,826,783 $52.9M
AQR Capital Management Held (±25%) −0.8% shares 1,279,473 $23.9M
Two Sigma Investments Trimmed −48.8% shares 700,921 $13.1M
Millennium Management Added +70.2% shares 591,675 $11.1M
Citadel Advisors Added +168.7% shares 473,682 $8.9M
Duquesne Family Office New position 349,000 $6.5M
Renaissance Technologies Trimmed −71.4% shares 192,399 $3.6M
Balyasny Asset Management Trimmed −96.3% shares 112,989 $2.1M
Marshall Wace Trimmed −98.1% shares 17,843 $334K
Man Group Trimmed −89.7% shares 11,618 $217K

Source: SEC EDGAR 13F filings

RLAY fails-to-deliver

SEC CNS data

On 14 Aug 2026, 42,458 shares of RLAY failed to deliver (about $846K).

Settlement date Shares failed Notional % of shares out
14 Aug 2026 42,458 $846K 0.019%
12 Aug 2026 4,154 $83K 0.002%
04 Aug 2026 25 $470 <0.001%

Source: SEC fails-to-deliver (CNS) data